Salvatore Siena

1.2k total papers · 79.5k total citations
534 papers, 37.6k citations indexed

About

Salvatore Siena is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Salvatore Siena has authored 534 papers receiving a total of 37.6k indexed citations (citations by other indexed papers that have themselves been cited), including 423 papers in Oncology, 251 papers in Pulmonary and Respiratory Medicine and 107 papers in Cancer Research. Recurrent topics in Salvatore Siena's work include Colorectal Cancer Treatments and Studies (268 papers), Lung Cancer Treatments and Mutations (142 papers) and Gastric Cancer Management and Outcomes (103 papers). Salvatore Siena is often cited by papers focused on Colorectal Cancer Treatments and Studies (268 papers), Lung Cancer Treatments and Mutations (142 papers) and Gastric Cancer Management and Outcomes (103 papers). Salvatore Siena collaborates with scholars based in Italy, United States and Spain. Salvatore Siena's co-authors include Alberto Bardelli, Andrea Sartore‐Bianchi, Eric Van Cutsem, Yves Humblet, Federica Di Nicolantonio, Marco Bregni, Silvia Marsoni, Marc Peeters, David Cunningham and Michael Wolf and has published in prestigious journals such as New England Journal of Medicine, Cell and The Lancet.

In The Last Decade

Salvatore Siena

522 papers receiving 36.7k citations

Hit Papers

Cetuximab Monotherapy and... 1989 2026 2001 2013 2004 2008 2012 2007 2017 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
    2004 3.9k citations David Cunningham, Yves Humblet et al. New England Journal of Medicine profile →
  2. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
    2008 2.4k citations Rafael G. Amado, Michael Wolf et al. Journal of Clinical Oncology profile →
  3. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
    2012 2.0k citations Axel Grothey, Eric Van Cutsem et al. The Lancet profile →
  4. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
    2007 1.5k citations Eric Van Cutsem, Marc Peeters et al. Journal of Clinical Oncology profile →
  5. Integrating liquid biopsies into the management of cancer
    2017 1.4k citations Giulia Siravegna, Silvia Marsoni et al. Nature Reviews Clinical Oncology profile →
  6. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
    2010 1.3k citations Jean‐Yves Douillard, Salvatore Siena et al. Journal of Clinical Oncology profile →
  7. Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
    2008 1.3k citations Federica Di Nicolantonio, Miriam Martini et al. Journal of Clinical Oncology profile →
  8. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
    2014 1.1k citations Marcia S. Brose, Christopher M. Nutting et al. The Lancet profile →
  9. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
    2005 773 citations Mauro Moroni, Silvio Veronese et al. The Lancet Oncology profile →
  10. Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies
    2007 672 citations Silvia Benvenuti, Andrea Sartore‐Bianchi et al. Cancer Research profile →
  11. PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
    2009 600 citations Andrea Sartore‐Bianchi, Miriam Martini et al. Cancer Research profile →
  12. GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION
    1989 588 citations Marco Bregni, A. Stern et al. The Lancet profile →
  13. Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
    2010 570 citations Wendy De Roock, Derek J. Jonker et al. JAMA profile →
  14. Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
    2010 540 citations Alberto Bardelli, Salvatore Siena Journal of Clinical Oncology profile →
  15. nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
    2015 503 citations David Goldstein, Robert H. El-Maraghi et al. JNCI Journal of the National Cancer Institute profile →
  16. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
    2016 421 citations Alessio Amatu, Andrea Sartore‐Bianchi et al. ESMO Open profile →
  17. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
    2012 418 citations Allan Lipton, Karim Fizazi et al. European Journal of Cancer profile →
  18. Early‐onset colorectal cancer in young individuals
    2018 407 citations Gianluca Mauri, Andrea Sartore‐Bianchi et al. Molecular Oncology profile →
  19. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
    2023 395 citations Funda Meric‐Bernstam, Vicky Makker et al. Journal of Clinical Oncology profile →
  20. Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
    2014 370 citations Sandra Misale, Federica Di Nicolantonio et al. Cancer Discovery profile →
  21. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
    2022 141 citations Vivek Subbiah, Philippe A. Cassier et al. Nature Medicine profile →
  22. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment
    2022 125 citations Pierfranco Conté, P.A. Ascierto et al. ESMO Open profile →
  23. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study
    2023 117 citations Eric Van Cutsem, Maria Di Bartolomeo et al. The Lancet Oncology profile →
  24. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
    2022 116 citations Charles A. Powell, Shanu Modi et al. ESMO Open profile →
  25. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
    2023 91 citations Takayuki Yoshino, Maria Di Bartolomeo et al. Nature Communications profile →
  26. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
    2024 42 citations Bob T. Li, Funda Meric‐Bernstam et al. The Lancet Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Salvatore Siena 26.6k 12.1k 8.5k 7.5k 7.0k 534 37.6k
John D. Hainsworth 21.5k 0.8× 12.3k 1.0× 7.0k 0.8× 10.1k 1.3× 5.2k 0.7× 632 37.1k
Armando Santoro 17.8k 0.7× 13.8k 1.1× 8.8k 1.0× 5.6k 0.7× 3.8k 0.5× 923 34.5k
Josep Tabernero 34.0k 1.3× 14.5k 1.2× 9.4k 1.1× 14.3k 1.9× 8.8k 1.3× 1.1k 50.3k
Heinz‐Josef Lenz 24.5k 0.9× 9.2k 0.8× 8.1k 1.0× 9.6k 1.3× 6.4k 0.9× 861 35.7k
Richard Pazdur 19.7k 0.7× 10.2k 0.8× 3.3k 0.4× 10.5k 1.4× 5.1k 0.7× 592 37.4k
Howard A. Burris 25.4k 1.0× 10.7k 0.9× 3.8k 0.5× 12.9k 1.7× 6.2k 0.9× 739 38.1k
Janet Dancey 19.8k 0.7× 15.3k 1.3× 3.3k 0.4× 8.5k 1.1× 6.2k 0.9× 205 38.1k
Fortunato Ciardiello 21.9k 0.8× 11.8k 1.0× 4.6k 0.5× 13.3k 1.8× 5.4k 0.8× 641 34.1k
M. van Glabbeke 15.5k 0.6× 17.9k 1.5× 4.3k 0.5× 4.5k 0.6× 3.3k 0.5× 197 35.3k
Louis Fehrenbacher 25.3k 0.9× 10.2k 0.8× 3.4k 0.4× 8.9k 1.2× 8.0k 1.1× 157 35.9k

Countries citing papers authored by Salvatore Siena

Since Specialization
Citations

This map shows the geographic impact of Salvatore Siena's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Salvatore Siena with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Salvatore Siena more than expected).

Fields of papers citing papers by Salvatore Siena

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Salvatore Siena. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Salvatore Siena. The network helps show where Salvatore Siena may publish in the future.

Co-authorship network of co-authors of Salvatore Siena

This figure shows the co-authorship network connecting the top 25 collaborators of Salvatore Siena. A scholar is included among the top collaborators of Salvatore Siena based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Salvatore Siena. Salvatore Siena is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James E. Herndon Breakdown of academic impact, for papers by Guillaume Maurin Breakdown of academic impact, for papers by Klaus F. Rabe Breakdown of academic impact, for papers by Asrar B. Malik Breakdown of academic impact, for papers by Kenneth B. Wiberg Breakdown of academic impact, for papers by Ka‐Fai To Breakdown of academic impact, for papers by Robert J. Norman Breakdown of academic impact, for papers by Charles G. Drake
Rankless by CCL
2026